Key Highlights

  • Profusa (NASDAQ:PFSA) traded at USD 0.7315, down 6.18%, in pre-market trading on Tuesday, October 27, 2026, with no company-specific announcement dated on or just before that session; the latest release is dated Thursday, October 15, 2026.
  • For the quarter ended June 30, 2026, reported on Thursday, August 20, 2026, the company disclosed a net loss of USD 8.8 million, USD 12.2 million for the first half, and cash of USD 719,000.
  • Total assets were USD 1.0 million against liabilities of USD 28.2 million at June 30, 2026, and the company holds an option to acquire G3 Vision Labs, signed on Friday, July 31, 2026.
  • Nasdaq confirmed bid price and equity compliance on Wednesday, September 9, 2026, but the company remains under a one-year Mandatory Panel Monitor; the quote is a thin snapshot.

The Pre-Market Move and Its Catalyst

Profusa (NASDAQ:PFSA), a medical technology company developing tissue-integrated biosensors, including the Lumee oxygen platform, traded at USD 0.7315, down 6.18%, in the pre-market snapshot of Tuesday, October 27, 2026. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The most recent release is the company's announcement of Thursday, October 15, 2026 that it had received an ISO 13485:2016 certificate for its quality management system from the notified body GMED. The decline therefore appears consistent with thin pre-market liquidity and the dilution overhang from the company's capital structure changes, which is an inference. Pre-market quotes can change before the open at 9:30 a.m. ET.

How the Latest Results Frame the Move

Profusa (NASDAQ:PFSA) reported on Thursday, August 20, 2026 a net loss of USD 8.8 million for the quarter ended June 30, 2026 and USD 12.2 million for the first half. Cash was USD 719,000, total assets were USD 1.0 million and liabilities were USD 28.2 million, which left a stockholders' deficit of USD 27.1 million. The company borrowed USD 650,000 for near-term needs. Debt and liability holders executed USD 10.7 million of Series A convertible exchange agreements, of which USD 4.57 million was exchanged into convertible preferred stock. The certificate of Thursday, October 15, 2026 covers manufacture at the Berkeley facility, although the European CE marking remains pending, so the balance sheet rather than the certificate is the dominant driver.

Risks and What to Watch

The bull reading rests on the manufacturing certificate, the conversion of liabilities into preferred stock and the option over G3 Vision Labs, whose 2025 net revenues are estimated at about USD 111 million on unaudited management information. The bear reading rests on cash of USD 719,000, a large liability base and the conditions attached to the option, including at least USD 30 million of aggregate financings. Named risks include dilution, listing compliance, because the one-year Mandatory Panel Monitor allows a delisting determination without a new compliance plan if the equity rule is failed, and regulatory timing for the European conformity assessment. Investors should watch the Federal Reserve decision on Wednesday, October 28, 2026, financing announcements, the G3 Vision exercise decision and the results for the quarter ending September 30, 2026.

Where Things Stand

The answer is that Profusa (NASDAQ:PFSA) slid 6.18% before the open without a dated company announcement, and the move appears consistent with thin liquidity and balance sheet concerns. The key number is cash of USD 719,000 at June 30, 2026, against liabilities of USD 28.2 million. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, any financing tied to the G3 Vision option and the results for the quarter ending September 30, 2026, for which no date has been announced. Pre-market prices are snapshots and can change, and this is not investment advice.